O	0	3	Fas	Fas	NN	B-NP
O	3	4	-	-	HYPH	I-NP
O	4	7	Fas	Fas	NN	I-NP
O	8	14	ligand	ligand	NN	I-NP
O	15	24	signaling	signaling	NN	I-NP
O	25	32	pathway	pathway	NN	I-NP
O	33	41	mediates	mediate	VBZ	B-VP
O	42	44	an	an	DT	B-NP
O	45	56	interleukin	interleukin	NN	I-NP
O	56	57	-	-	HYPH	B-NP
O	57	59	12	12	CD	I-NP
O	59	60	-	-	HYPH	I-NP
O	60	67	induced	induce	VBN	I-NP
O	68	77	rejection	rejection	NN	I-NP
O	78	80	of	of	IN	B-PP
O	81	82	a	a	DT	B-NP
O	83	89	murine	murine	JJ	I-NP
B-Cancer	90	98	prostate	prostate	NN	I-NP
I-Cancer	99	104	tumor	tumor	NN	I-NP
O	105	111	system	system	NN	I-NP
O	111	112	.	.	.	O

O	114	124	BACKGROUND	BACKGROUND	NN	B-NP
O	124	125	:	:	:	O
O	126	132	Recent	Recent	JJ	B-NP
O	133	137	data	datum	NNS	I-NP
O	138	145	suggest	suggest	VBP	B-VP
O	146	150	that	that	IN	B-SBAR
O	151	155	anti	anti	AFX	B-NP
O	155	156	-	-	HYPH	I-NP
B-Cancer	156	161	tumor	tumor	NN	I-NP
O	162	172	activities	activity	NNS	I-NP
O	173	175	of	of	IN	B-PP
O	176	187	interleukin	interleukin	NN	B-NP
O	187	188	-	-	HYPH	B-NP
O	188	190	12	12	CD	I-NP
O	191	192	(	(	(	O
O	192	194	IL	IL	NN	B-NP
O	194	195	-	-	HYPH	B-NP
O	195	197	12	12	CD	I-NP
O	197	198	)	)	)	O
O	199	206	involve	involve	VBP	B-VP
O	207	210	the	the	DT	B-NP
O	211	220	induction	induction	NN	I-NP
O	221	223	of	of	IN	B-PP
O	224	233	apoptosis	apoptosis	NN	B-NP
O	233	234	.	.	.	O

O	235	238	Fas	Fas	NN	B-NP
O	239	240	(	(	(	O
O	240	243	APO	APO	NN	B-NP
O	243	244	-	-	HYPH	B-NP
O	244	245	1	1	CD	I-NP
O	245	246	/	/	SYM	I-NP
O	246	250	CD95	CD95	NN	I-NP
O	250	251	)	)	)	O
O	252	254	is	be	VBZ	B-VP
O	255	256	a	a	DT	B-NP
O	257	261	type	type	NN	I-NP
O	262	263	I	I	CD	I-NP
B-Cellular_component	264	272	membrane	membrane	NN	I-NP
O	273	280	protein	protein	NN	I-NP
O	281	285	that	that	WDT	B-NP
O	286	288	is	be	VBZ	B-VP
O	289	296	capable	capable	JJ	B-ADJP
O	297	299	of	of	IN	B-PP
O	300	310	initiating	initiate	VBG	B-VP
O	311	313	an	an	DT	B-NP
O	314	323	apoptosis	apoptosis	NN	I-NP
O	324	333	signaling	signaling	NN	I-NP
O	334	341	pathway	pathway	NN	I-NP
O	342	346	when	when	WRB	B-ADVP
O	347	352	bound	bind	VBN	B-VP
O	353	355	to	to	TO	B-PP
O	356	359	its	its	PRP$	B-NP
O	360	366	ligand	ligand	NN	I-NP
O	367	368	(	(	(	O
O	368	372	FasL	FasL	NN	B-NP
O	372	373	)	)	)	O
O	373	374	.	.	.	O

O	375	377	We	We	PRP	B-NP
O	378	387	undertook	undertake	VBD	B-VP
O	388	392	this	this	DT	B-NP
O	393	398	study	study	NN	I-NP
O	399	401	to	to	TO	B-VP
O	402	406	test	test	VB	I-VP
O	407	410	the	the	DT	B-NP
O	411	421	hypothesis	hypothesis	NN	I-NP
O	422	426	that	that	IN	B-SBAR
O	427	430	Fas	Fas	NN	B-NP
O	430	431	-	-	HYPH	B-NP
O	431	435	FasL	FasL	NN	I-NP
O	435	436	-	-	HYPH	O
O	436	444	mediated	mediate	VBN	B-NP
O	445	454	apoptosis	apoptosis	NN	I-NP
O	455	460	plays	play	VBZ	B-VP
O	461	462	a	a	DT	B-NP
O	463	467	role	role	NN	I-NP
O	468	470	in	in	IN	B-PP
O	471	473	IL	IL	NN	B-NP
O	473	474	-	-	HYPH	B-NP
O	474	476	12	12	CD	I-NP
O	476	477	-	-	HYPH	B-NP
O	477	484	induced	induce	VBN	I-NP
B-Cancer	485	490	tumor	tumor	NN	I-NP
O	491	501	regression	regression	NN	I-NP
O	501	502	.	.	.	O

O	503	510	METHODS	METHODS	NNS	B-NP
O	510	511	:	:	:	O
O	512	514	An	An	DT	B-NP
O	515	518	mIL	mIL	NN	I-NP
O	518	519	-	-	HYPH	B-NP
O	519	521	12	12	CD	I-NP
O	522	532	expression	expression	NN	I-NP
O	533	539	vector	vector	NN	I-NP
O	540	546	driven	drive	VBN	B-VP
O	547	549	by	by	IN	B-PP
O	550	565	cytomegalovirus	cytomegalovirus	NN	B-NP
O	566	574	promoter	promoter	NN	I-NP
O	575	578	was	be	VBD	B-VP
O	579	583	used	use	VBN	I-VP
O	584	586	to	to	TO	B-VP
O	587	594	express	express	VB	I-VP
O	595	601	murine	murine	JJ	B-NP
O	602	604	IL	IL	NN	I-NP
O	604	605	-	-	HYPH	B-NP
O	605	607	12	12	CD	I-NP
O	608	612	cDNA	cDNA	NN	I-NP
O	613	615	in	in	IN	B-PP
O	616	619	the	the	DT	B-NP
B-Cell	620	622	RM	RM	NN	I-NP
I-Cell	622	623	-	-	HYPH	B-NP
I-Cell	623	624	9	9	CD	I-NP
I-Cell	625	631	murine	murine	JJ	I-NP
I-Cell	632	640	prostate	prostate	NN	I-NP
I-Cell	641	650	carcinoma	carcinoma	NN	I-NP
I-Cell	651	655	cell	cell	NN	I-NP
I-Cell	656	660	line	line	NN	I-NP
O	660	661	.	.	.	O

O	662	669	Control	Control	NN	B-NP
B-Cell	670	672	RM	RM	NN	I-NP
I-Cell	672	673	-	-	HYPH	O
I-Cell	673	674	9	9	CD	B-NP
I-Cell	675	680	cells	cell	NNS	I-NP
O	681	684	and	and	CC	O
B-Cell	685	687	RM	RM	NN	B-NP
I-Cell	687	688	-	-	HYPH	O
I-Cell	688	689	9	9	CD	B-NP
I-Cell	690	695	cells	cell	NNS	I-NP
O	696	702	stably	stably	RB	B-VP
O	703	714	transfected	transfecte	VBN	I-VP
O	715	719	with	with	IN	B-PP
O	720	722	IL	IL	NN	B-NP
O	722	723	-	-	HYPH	B-NP
O	723	725	12	12	CD	I-NP
O	726	730	gene	gene	NN	I-NP
O	731	732	(	(	(	O
B-Cell	732	734	RM	RM	NN	B-NP
I-Cell	734	735	-	-	HYPH	B-NP
I-Cell	735	736	9	9	CD	I-NP
I-Cell	736	737	-	-	HYPH	I-NP
I-Cell	737	741	IL12	IL12	NN	I-NP
O	741	742	)	)	)	O
O	743	747	were	be	VBD	B-VP
O	748	758	inoculated	inoculate	VBN	I-VP
B-Immaterial_anatomical_entity	759	773	subcutaneously	subcutaneously	RB	B-ADVP
O	774	776	in	in	IN	B-PP
O	777	778	4	4	CD	B-NP
O	778	779	-	-	HYPH	B-ADJP
O	780	782	to	to	TO	B-PP
O	783	784	6	6	CD	B-NP
O	784	785	-	-	HYPH	B-NP
O	785	789	week	week	NN	I-NP
O	789	790	-	-	HYPH	O
O	790	793	old	old	JJ	B-NP
O	794	798	male	male	JJ	I-NP
O	799	804	C57BL	C57BL	NN	I-NP
O	804	805	/	/	SYM	B-VP
O	805	807	J6	J6	NN	B-NP
O	808	812	mice	mouse	NNS	I-NP
O	812	813	.	.	.	O

B-Cancer	814	819	Tumor	Tumor	NN	B-NP
O	820	824	size	size	NN	I-NP
O	825	828	was	be	VBD	B-VP
O	829	837	measured	measure	VBN	I-VP
O	838	843	every	every	DT	B-NP
O	844	845	3	3	CD	I-NP
O	846	850	days	day	NNS	I-NP
O	850	851	.	.	.	O

O	852	859	Western	Western	NN	B-NP
O	860	864	blot	blot	NN	I-NP
O	865	868	and	and	CC	O
O	869	888	immunohistochemical	immunohistochemical	JJ	B-NP
O	889	895	assays	assay	NNS	I-NP
O	896	900	were	be	VBD	B-VP
O	901	905	used	use	VBN	I-VP
O	906	908	to	to	TO	B-VP
O	909	917	evaluate	evaluate	VB	I-VP
O	918	921	Fas	Fas	NN	B-NP
O	922	925	and	and	CC	I-NP
O	926	930	FasL	FasL	NN	I-NP
O	931	938	protein	protein	NN	I-NP
O	939	949	expression	expression	NN	I-NP
O	949	950	.	.	.	O

O	951	953	In	In	FW	B-ADVP
O	954	958	situ	situ	FW	I-ADVP
O	959	970	fluorescent	fluorescent	JJ	B-NP
O	971	974	end	end	NN	I-NP
O	975	983	labeling	labeling	NN	I-NP
O	984	987	was	be	VBD	B-VP
O	988	992	used	use	VBN	I-VP
O	993	995	to	to	TO	B-VP
O	996	1001	label	label	VB	I-VP
O	1002	1011	apoptotic	apoptotic	JJ	B-NP
B-Cell	1012	1017	cells	cell	NNS	I-NP
O	1017	1018	.	.	.	O

O	1019	1026	RESULTS	RESULTS	NNS	B-NP
O	1026	1027	:	:	:	O
O	1028	1030	IL	IL	NN	B-NP
O	1030	1031	-	-	HYPH	B-NP
O	1031	1033	12	12	CD	I-NP
O	1033	1034	-	-	HYPH	I-NP
O	1034	1044	expressing	express	VBG	I-NP
B-Cell	1045	1047	RM	RM	NN	I-NP
I-Cell	1047	1048	-	-	HYPH	I-NP
I-Cell	1048	1049	9	9	CD	I-NP
I-Cell	1050	1058	prostate	prostate	NN	I-NP
I-Cell	1059	1068	carcinoma	carcinoma	NN	I-NP
I-Cell	1069	1074	cells	cell	NNS	I-NP
O	1075	1087	transplanted	transplant	VBN	B-VP
O	1088	1092	into	into	IN	B-PP
O	1093	1098	C57BL	C57BL	NN	B-NP
O	1098	1099	/	/	SYM	B-NP
O	1099	1101	J6	J6	NN	I-NP
O	1102	1106	mice	mouse	NNS	I-NP
O	1107	1111	grew	grow	VBD	B-VP
O	1112	1116	more	more	RBR	B-ADVP
O	1117	1123	slowly	slowly	RB	I-ADVP
O	1124	1128	than	than	IN	B-PP
O	1129	1136	control	control	NN	B-NP
B-Cell	1137	1139	RM	RM	NN	I-NP
I-Cell	1139	1140	-	-	HYPH	O
I-Cell	1140	1141	9	9	CD	B-NP
I-Cell	1142	1147	cells	cell	NNS	I-NP
O	1148	1151	and	and	CC	O
O	1152	1158	vector	vector	NN	B-NP
O	1159	1166	control	control	NN	I-NP
B-Cell	1167	1169	RM	RM	NN	I-NP
I-Cell	1169	1170	-	-	HYPH	B-NP
I-Cell	1170	1171	9	9	CD	I-NP
I-Cell	1171	1172	-	-	HYPH	I-NP
I-Cell	1172	1175	Luc	Luc	NN	I-NP
I-Cell	1176	1181	cells	cell	NNS	I-NP
O	1181	1182	.	.	.	O

O	1183	1186	The	The	DT	B-NP
O	1187	1194	average	average	JJ	I-NP
O	1195	1203	survival	survival	NN	I-NP
O	1204	1208	time	time	NN	I-NP
O	1209	1211	of	of	IN	B-PP
O	1212	1215	the	the	DT	B-NP
B-Cell	1216	1218	RM	RM	NN	I-NP
I-Cell	1218	1219	-	-	HYPH	B-NP
I-Cell	1219	1220	9	9	CD	I-NP
I-Cell	1220	1221	-	-	HYPH	I-NP
I-Cell	1221	1225	IL12	IL12	NN	I-NP
O	1226	1230	mice	mouse	NNS	I-NP
O	1231	1234	was	be	VBD	B-VP
O	1235	1241	longer	long	JJR	B-ADJP
O	1242	1246	than	than	IN	B-PP
O	1247	1249	53	53	CD	B-NP
O	1250	1254	days	day	NNS	I-NP
O	1254	1255	,	,	,	O
O	1256	1263	whereas	whereas	IN	O
O	1264	1267	the	the	DT	B-NP
O	1268	1272	mean	mean	JJ	I-NP
O	1273	1281	survival	survival	NN	I-NP
O	1282	1285	for	for	IN	B-PP
O	1286	1290	mice	mouse	NNS	B-NP
O	1291	1303	transplanted	transplant	VBN	B-VP
O	1304	1308	with	with	IN	B-PP
O	1309	1316	control	control	NN	B-NP
B-Cell	1317	1319	RM	RM	NN	I-NP
I-Cell	1319	1320	-	-	HYPH	B-NP
I-Cell	1320	1321	9	9	CD	I-NP
I-Cell	1322	1327	cells	cell	NNS	I-NP
O	1328	1331	was	be	VBD	B-VP
O	1332	1336	only	only	RB	B-NP
O	1337	1339	16	16	CD	I-NP
O	1340	1344	days	day	NNS	I-NP
O	1344	1345	.	.	.	O

O	1346	1355	Apoptotic	Apoptotic	JJ	B-NP
B-Cell	1356	1361	cells	cell	NNS	I-NP
O	1362	1366	were	be	VBD	B-VP
O	1367	1371	more	more	RBR	B-ADJP
O	1372	1380	numerous	numerous	JJ	I-ADJP
O	1381	1383	in	in	IN	B-PP
B-Cancer	1384	1386	RM	RM	NN	B-NP
I-Cancer	1386	1387	-	-	HYPH	B-NP
I-Cancer	1387	1388	9	9	CD	I-NP
I-Cancer	1388	1389	-	-	HYPH	I-NP
I-Cancer	1389	1393	IL12	IL12	NN	I-NP
I-Cancer	1394	1400	tumors	tumor	NNS	I-NP
O	1400	1401	:	:	:	O
O	1402	1404	10	10	CD	B-NP
O	1404	1405	.	.	.	O
O	1405	1406	3	3	CD	B-NP
O	1406	1407	%	%	NN	I-NP
O	1408	1410	vs	v	NNS	I-NP
O	1410	1411	.	.	.	O
O	1412	1413	1	1	CD	B-NP
O	1413	1414	.	.	.	O
O	1414	1415	5	5	CD	B-NP
O	1415	1416	%	%	NN	I-NP
O	1417	1419	in	in	IN	B-PP
O	1420	1427	control	control	NN	B-NP
O	1428	1429	(	(	(	O
O	1429	1430	P	P	NN	B-NP
O	1431	1432	=	=	SYM	B-VP
O	1433	1434	0	0	CD	B-NP
O	1434	1435	.	.	SYM	I-NP
O	1435	1438	001	001	CD	I-NP
O	1438	1439	)	)	)	O
O	1439	1440	.	.	.	O

O	1441	1444	Fas	Fas	NN	B-NP
O	1445	1448	and	and	CC	I-NP
O	1449	1453	FasL	FasL	NN	I-NP
O	1454	1462	proteins	protein	NNS	I-NP
O	1463	1467	were	be	VBD	B-VP
O	1468	1477	increased	increase	VBN	I-VP
O	1478	1491	approximately	approximately	RB	B-ADVP
O	1492	1499	twofold	twofold	RB	I-ADVP
O	1500	1502	in	in	IN	B-PP
O	1503	1506	the	the	DT	B-NP
B-Cancer	1507	1509	RM	RM	NN	I-NP
I-Cancer	1509	1510	-	-	HYPH	B-NP
I-Cancer	1510	1511	9	9	CD	I-NP
I-Cancer	1511	1512	-	-	HYPH	I-NP
I-Cancer	1512	1516	IL12	IL12	NN	I-NP
I-Cancer	1517	1523	tumors	tumor	NNS	I-NP
O	1524	1532	compared	compare	VBN	B-PP
O	1533	1537	with	with	IN	B-PP
O	1538	1541	the	the	DT	B-NP
B-Cancer	1542	1544	RM	RM	NN	I-NP
I-Cancer	1544	1545	-	-	HYPH	O
I-Cancer	1545	1546	9	9	CD	B-NP
I-Cancer	1547	1554	control	control	NN	I-NP
I-Cancer	1555	1561	tumors	tumor	NNS	I-NP
O	1562	1564	as	as	IN	B-SBAR
O	1565	1575	determined	determine	VBN	B-VP
O	1576	1578	by	by	IN	B-PP
O	1579	1586	Western	Western	JJ	B-NP
O	1587	1591	blot	blot	NN	I-NP
O	1592	1595	and	and	CC	O
O	1596	1615	immunohistochemical	immunohistochemical	JJ	B-NP
O	1616	1624	analyses	analysis	NNS	I-NP
O	1625	1626	(	(	(	O
O	1626	1627	P	P	NN	B-NP
O	1628	1629	<	<	SYM	B-ADJP
O	1630	1631	0	0	CD	B-NP
O	1631	1632	.	.	.	I-NP
O	1632	1634	05	05	CD	I-NP
O	1634	1635	)	)	)	O
O	1635	1636	.	.	.	O

O	1637	1647	CONCLUSION	CONCLUSION	NN	B-NP
O	1647	1648	:	:	:	O
O	1649	1652	The	The	DT	B-NP
O	1653	1656	Fas	Fas	NN	I-NP
O	1656	1657	-	-	HYPH	B-NP
O	1657	1661	FasL	FasL	NN	I-NP
O	1661	1662	-	-	HYPH	B-NP
O	1662	1670	mediated	mediate	VBN	I-NP
O	1671	1680	apoptosis	apoptosis	NN	I-NP
O	1681	1688	pathway	pathway	NN	I-NP
O	1689	1692	may	may	MD	B-VP
O	1693	1703	contribute	contribute	VB	I-VP
O	1704	1706	to	to	TO	B-PP
O	1707	1710	the	the	DT	B-NP
O	1711	1713	IL	IL	NN	I-NP
O	1713	1714	-	-	HYPH	B-NP
O	1714	1716	12	12	CD	I-NP
O	1716	1717	-	-	HYPH	B-NP
O	1717	1724	induced	induce	VBN	I-NP
O	1725	1734	rejection	rejection	NN	I-NP
O	1735	1737	of	of	IN	B-PP
B-Cancer	1738	1746	prostate	prostate	NN	B-NP
I-Cancer	1747	1756	carcinoma	carcinoma	NN	I-NP
O	1756	1757	.	.	.	O

